Schibsted ASA (SCHA/SCHB) - Interim Financial Statement Q4

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
44
Schibsted ASA (SCHA/SCHB) - Interim Financial Statement Q4 2018

  Today, Schibsted Media Group released its Q4 2018 report. The revenue grew 6 percent to NOK 4,742 million, whereas the EBITDA grew 29 percent to NOK 897 million.

"After onboarding Schibsted at the beginning of December 2018, I am proud and happy to be able to present a strong set of Q4 results. An EBITDA of NOK 897 million is our highest quarterly profit ever, and it is 29 percent higher than in the same period in 2017," CEO Kristin Skogen Lund says.

"The improved profitability was driven by both our Marketplaces operations, where revenue and margins continued to grow well, and our Publishing operations, where the revenue grew in combination with good cost control," CEO Kristin Skogen Lund says.

"Within Marketplaces, our French operation delivered solid revenue growth in Q4 combined with margin improvement. At the same time, the operations in Norway and Spain continued their strong development. Sweden is still on the soft side, but we see an improved trajectory in underlying KPIs. Across many of our operations, we see strong growth in revenue from the verticals, whereas display advertising shows weaker trends," CEO Kristin Skogen Lund says.

"Once again we continued to reduce our investment phase losses, even though OLX in Brazil concentrated a large part of their annual marketing spend in Q4. The cost reduction in Shpock has continued, as we have communicated earlier," CEO Kristin Skogen Lund says.

"When it comes to Publishing, I am impressed by the Q4 achievement, with improved profitability, supported by strong growth in digital subscription revenue and digital advertising sales. The foundation of this positive development is the high standards of quality and relevance which guide our editorial teams. Also in Q4, we have been able to set the public agenda both in Norway and Sweden on several occasions," CEO Kristin Skogen Lund says.

"The operations in Schibsted Growth had a soft development in terms of revenue and profits in Q4. The successful loan comparison site, Lendo, continues to be a key growth driver in this segment though partly curbed by the Norwegian market due to new regulatory initiatives. Lendo has been expanded into the Danish market, and we believe it is possible to repeat Lendo's success both here and in other geographies," CEO Kristin Skogen Lund says.

Highlights of Q4 2018

  • Marketplaces: Revenues continue to grow, and profits increase
    • Revenues up 14 percent*; EBITDA margin up 3%-points to 32 percent*
    • Revenues from verticals grew 20 percent, while the growth in display advertising revenues was lower than in previous quarters
    • France, Spain, Norway and Brazil with solid growth in Q4
    • Margin improvement in France in Q4 - Leboncoin.fr EBITDA margin 62 percent (57%)
    • In Q1 2019, Schibsted acquired 10 percent of SCM Spain, increasing the ownership to 100 percent
    • Investment phase losses continued to decline in Q4 compared to Q4 2017
  • Publishing: Growing revenues driven by digital products
    • 3 percent total revenue increase in Q4; strong digital growth and 10 percent EBITDA margin (10%)
  • Schibsted Growth: Continues to expand
    • Continued growth for Lendo, but with lower rate than in previous quarters. Launched in Denmark in Q4, which affects margins negatively in the ramp-up phase
    • Prisjakt with strong development in 2018, full-year revenue of NOK 308 million (+18% growth) and 31% EBITDA margin
  • The operating profit and net profit of the group is negatively affected by a non-cash impairment loss of NOK 601 million in Yapo (Chile) and Compricer (Sweden). Adjusted EPS increased 109% to NOK 1.84
  • Spin off of the international marketplaces operations on track for separate listing as of 10 April 2019
  • Kristin Skogen Lund onboarded as new CEO of Schibsted 1 December
  • Dividend of NOK 2.00 per share proposed for 2018

*) Including proportionate share of JVs, adjusted for currency

Fourth quarter  (NOK million)  Year
2017 2018  SCHIBSTED MEDIA GROUP  2018 2017
  4,455   4,742  Operating revenues   18,059   16,943
  695   897  EBITDA   3,268   2,606
16 % 19 %  EBITDA margin 18 % 15 %
  840   975  EBITDA excl. Investment phase   3,709   3,282
19 % 21 %  EBITDA margin excl. Investment phase 21 % 20 %

Schibsted invites to an analyst and press conference at Akersgata 55, Oslo, 13 February 2019 at 10:00 CET (NOTE: NEW TIME) . The presentation will be held in English and transmitted live as a video webcast on https://www.schibsted.com/ir/ . CEO Kristin Skogen Lund, CEO of MPI Rolv Erik Ryssdal and EVP CFO Trond Berger will present at the analyst and press conference.

A conference call with Q&A linked to the Q4 2018 numbers will take place 13 February 2019 at 14:00 CET. The session will be held in English.

NOTE: To avoid waiting time when connecting to the call, please use the below link 5-10 minutes prior to start time, where you will be asked to type in your phone number and registration details. The Event Conferencing system will automatically call you back on the phone number you provide and place you into the event. Please note that the link will become active 15 minutes prior to the event: Link to join call: https://bit.ly/2t8UP5N

For manual dial-in, use the following number (note that this connection might take more time): +47 2350 0187. Passcode:  200225 . For additional phone number, please visit  https://www.schibsted.com/ir/ .

Contact persons: Trond Berger, CFO. Tel: +47 916 86 695 Jo Christian Steigedal, Head of IR. Tel: +47 415 08 733

Oslo, 13 February 2019 SCHIBSTED ASA

Jo Christian Steigedal Head of IR

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

Attachments

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 105

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 228

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 13

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 29

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 28

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 60

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 47

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
2GenPen's Patent Push: Transforming Credit Analysis

Updated Category News Views 7

Changing the Game in Credit Analysis When you hear about a company snagging a patent, it's usually a big whoop-de-do; but 2GenPen's latest achievement is making some serious waves. This isn't some 'pat-yourself-on-the-back' sort of news – it's got teeth in the world of finance. These folks just locked down their second U.S. patent, number 12,784,096, and it's all about...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 131

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Innovation: Schneider Electric's Climate Tech Event

Updated Category News Views 170

Exploring the Excitement of the Climate Tech in the City Event The Climate Tech in the City event embodies the spirit of innovation, uniting key players in the climate technology sector. Leading organizations like Schneider Electric are at the forefront, showcasing groundbreaking advancements and sustainable practices. This year's gathering promises a vibrant day filled...

Continue Reading
Ouster Transforms Chattanooga into a Smart Traffic Hub

Updated Category News Views 404

Ouster's Groundbreaking Initiative in Smart Traffic Management In a significant development for urban traffic management, Ouster, Inc. (NASDAQ: OUST), recognized for its state-of-the-art lidar sensors, has launched a transformative project in Chattanooga. This venture stands out as the largest lidar-enabled traffic system in the United States, boasting a remarkable...

Continue Reading
Bicara Therapeutics Business Highlights and Q1 2025 Financial Review

Updated Category News Views 520

Bicara Therapeutics Announces Key Developments and Q1 2025 Financial Results Latest data from ongoing clinical trials to be showcased at upcoming conferences. Strong financial position enables sustained development through 2029. Bicara Therapeutics Inc. (Nasdaq: BCAX), a pioneering clinical-stage biopharmaceutical firm, focuses on delivering groundbreaking bifunctional...

Continue Reading
IO Biotech Gears Up for December Conferences: Insights and Highlights

Updated Category News Views 148

IO Biotech Prepares for Key Investor Conferences IO Biotech, a trailblazer in developing groundbreaking immune-modulatory cancer vaccines, is set to join two prominent investor events this December. The company, listed under NASDAQ: IOBT, is known for its innovative approach in the biopharmaceutical industry, particularly in creating off-the-shelf therapeutic cancer...

Continue Reading
Cardinal Energy Secures $40 Million Through Latest Debenture Offering

Updated Category News Views 267

Cardinal Energy Ltd. Announces a Major Offering Cardinal Energy Ltd. is excited to inform investors about its latest initiative aimed at raising funds through a significant offering. The company has entered into an agreement with a selected group of underwriters who will help facilitate the sale of $40 million in senior subordinated unsecured debentures. This strategic...

Continue Reading